Uploaded on Jun 26, 2024
According to the latest research report by IMARC Group, The North America HIV drugs market size reached US$ 22.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.6 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. More Info:- https://www.imarcgroup.com/north-america-hiv-drugs-market
North America HIV Drugs Market by Product Type, Distribution Channel, End User 2024-2032
North America HIV
Drugs Market Research
and Forecast Report
2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved
About IMARC Group
In ternat ional Market Analys is Research and Consul t ing Group is a leading adv iser on management
s t rategy and market research wor ldwide. We par tner wi th c l ients in a l l regions and indust ry
vert ica ls to ident i fy thei r h ighest -value oppor tuni t ies, address thei r most cr i t ica l chal lenges, and
t ransform thei r bus inesses.
IMARC’s in format ion products inc lude major market , sc ient i f ic , economic and technological
developments for bus iness leaders in pharmaceut ica l , indust r ia l , and h igh technology
organizat ions. Market forecasts and indust ry analys is for b iotechnology, advanced mater ia ls ,
chemicals , food and beverage, t ravel and tour ism, nanotechnology and novel process ing methods
are at the top of the company’s exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight in to the dynamics o f companies and
markets wi th c lose cooperat ion at a l l levels of the c l ient organizat ion. This ensures that our c l ients
achieve unmatchable compet i t ive advantage, bui ld more pro f ic ient organizat ions, and secure
las t ing resul ts .
A c c o r d i n g t o t h e l a t e s t r e p o r t b y I M A R C G r o u p , t i t l e d " N o r t h A m e r i c a H I V D r u g s M a r k e t :
I n d u s t r y T r e n d s , S h a r e , S i z e , G r o w t h , O p p o r t u n i t y a n d F o r e c a s t 2 0 2 4 - 2 0 3 2 , " t h e N o r t h
A m e r i c a H I V d r u g s m a r k e t s i z e r e a c h e d U S $ 2 2 . 7 B i l l i o n i n 2 0 2 3 .
H I V d r u g s , a l s o k n o w n a s a n t i r e t r o v i r a l d r u g s , f o r m a c l a s s o f m e d i c a t i o n s s p e c i f i c a l l y
d e s i g n e d t o t r e a t H I V ( H u m a n I m m u n o d e f i c i e n c y V i r u s ) , t h e v i r u s r e s p o n s i b l e f o r A I D S . T h e s e
Report d r u g s d o n o t c u r e H I V b u t w o r k b y i n h i b i t i n g t h e v i r u s ' s a b i l i t y t o r e p l i c a t e a n d s p r e a d w i t h i n t h e h o s t ' s b o d y , t h e r e b y r e d u c i n g t h e v i r a l l o a d t o u n d e t e c t a b l e l e v e l s a n d i m p r o v i n g t h e
i m m u n e s y s t e m ' s f u n c t i o n . T h e e f f e c t i v e n e s s o f H I V t r e a t m e n t h i n g e s o n a r e g i m e n k n o w n a s
Highlight and a n t i r e t r o v i r a l t h e r a p y ( A R T ) , w h i c h t y p i c a l l y i n v o l v e s a c o m b i n a t i o n o f d i f f e r e n t c l a s s e s o f m e d i c a t i o n s . T h e s e c l a s s e s i n c l u d e n u c l e o s i d e r e v e r s e t r a n s c r i p t a s e i n h i b i t o r s ( N R T I s ) , n o n -
n u c l e o s i d e r e v e r s e t r a n s c r i p t a s e i n h i b i t o r s ( N N R T I s ) , p r o t e a s e i n h i b i t o r s ( P I s ) , e n t r y
Description i n h i b i t o r s , a n d i n t e g r a s e s t r a n d t r a n s f e r i n h i b i t o r s ( I N S T I s ) . T h e s t r a t e g i c c o m b i n a t i o n o f t h e s e d r u g s h e l p s p r e v e n t t h e v i r u s f r o m b e c o m i n g r e s i s t a n t t o a n y s i n g l e d r u g , e n h a n c i n g t h e
t h e r a p y ' s o v e r a l l e f f e c t i v e n e s s . O v e r t h e y e a r s , a d v a n c e m e n t s i n p h a r m a c e u t i c a l t e c h n o l o g i e s
h a v e l e d t o t h e d e v e l o p m e n t o f s i n g l e - p i l l r e g i m e n s t h a t c o m b i n e m u l t i p l e H I V d r u g s ,
s i g n i f i c a n t l y s i m p l i f y i n g t r e a t m e n t p r o t o c o l s , i m p r o v i n g a d h e r e n c e , a n d e n h a n c i n g p a t i e n t s '
q u a l i t y o f l i f e .
R e q u e s t f o r a P D F s a m p l e o f t h i s r e p o r t :
h t t p s : / / w w w . i m a r c g r o u p . c o m / n o r t h - a m e r i c a - h i v - d r u g s - m a r k e t / r e q u e s t s a m p l e
Report Description
N o r t h A m e r i c a H IV D r u g s M a r k e t T r e n d s :
T h e N o r t h A m e r i c a H I V d r u g s m a r k e t i s e x p e r i e n c i n g r o b u s t g r o w t h , d r i v e n b y s e v e r a l k e y f a c t o r s . I n c r e a s i n g p r e v a l e n c e o f H I V
i n f e c t i o n s a n d g o v e r n m e n t i n i t i a t i v e s t o c o m b a t t h e e p i d e m i c a r e s i g n i f i c a n t m a r k e t d r i v e r s . I n t h e U n i t e d S t a t e s a n d C a n a d a ,
c o m p r e h e n s i v e p u b l i c h e a l t h c a m p a i g n s a i m t o i n c r e a s e a w a r e n e s s , t e s t i n g , a n d t r e a t m e n t a d h e r e n c e , a l l o f w h i c h c o n t r i b u t e t o
t h e d e m a n d f o r a n t i r e t r o v i r a l d r u g s . T e c h n o l o g i c a l a d v a n c e m e n ts i n d r u g d e v e l o p m e n t h a v e a l s o p l a y e d a c r u c i a l r o l e . M o d e r n
H I V t r e a tm e n t s a r e m o r e e f f e c t i v e , h a v e f e w e r s i d e e f f e c t s , a n d o f f e r e a s i e r d o s i n g s c h e d u l e s t h a n e a r l i e r i t e r a t i o n s , f a c to r s t h a t
s i g n i f i c a n t l y i m p r o v e p a t i e n t a d h e r e n c e a n d t r e a t m e n t o u t c o m e s .
M o r e o v e r , t h e r i s e o f g e n e r i c d r u g o p t i o n s h a s m a d e t r e a t m e n t m o r e a c c e s s i b l e a n d a f f o r d a b l e , s u p p o r t i n g w i d e s p r e a d a d o p t i o n
a c r o s s d i f f e r e n t d e m o g r a p h i c s . T h e m a r k e t i s a l s o w i t n e s s i n g a t r e n d t o w a r d s p e r s o n a l i z e d m e d i c i n e , w h e r e t r e a t me n t s a r e
t a i l o r e d t o i n d i v i d u a l g e n e t i c p r o f i l e s t o o p t i m i z e e f f i c a c y a n d m i n i m i z e s i d e e f f e c t s . T h i s a p p r o a c h i s e x p e c te d t o e n h a n c e p a t i e n t
o u t c o m e s a n d d r i v e f u r t h e r m a r k e t g r o w th . A d d i t i o n a l l y , o n g o i n g r e s e a r c h a n d d e v e l o p m e n t a c t i v i t i e s f o c u s e d o n d i s c o v e r i n g
n o v e l t h e r a p e u t i c t a r g e t s a n d i m p r o v i n g e x i s t i n g f o r m u l a t i o n s a r e p i v o ta l m a r k e t t r e n d s . T h e s e f a c t o r s c o l l e c t i v e l y c o n t r i b u t e t o a
d y n a m i c a n d e x p a n d i n g m a r k e t l a n d s c a p e f o r H IV d r u g s i n N o r t h A m e r i c a , w i t h o n g o i n g d e v e l o p m e n ts p r o m i s i n g t o s h a p e t h e
f u t u r e t r a j e c to r y o f H I V t r e a t m e n t a n d ma n a g e m e n t .
V ie w R e p o r t T O C , F i g u r e s a n d T a b l e s : h t t p s : / / w w w . i m a r c g r o u p . c o m / n o r t h - a m e r i c a - h i v - d r u g s - m a r k e t
Market by Drug Class
• Nucleoside Reverse Transcr iptase Inhibitors
• Mult i -Class Combination Products
• Protease Inhibitors
• HIV Integrase Strand Transfer Inhibitors
Report • Non-Nucleoside Reverse Transcr iptase
Inhibitors
Segmentation • Entry Inhibitors—CCR5 Co-Receptor Antagonist
• Others
Market by Distribution Channel:
• Hospi ta l Pharmacies
• Retai l Pharmacies
• Online Pharmacies
• Others
Key Regions Analyzed
• United States
Report • Canada
Segmentation
How has the North America HIV drugs market
performed so far and how will it perform in the coming
years?
What are the key regions in the North America HIV
drugs market?
Key
Questions What has been the impact of COVID-19 on the North America HIV drugs market?
Answered in
What is the breakup of the North America HIV drugs
the Report market on the basis of drug class?
What is the breakup of the North America HIV drugs
market on the basis of distribution channel?
What are the various stages in the value chain of the
North America HIV drugs industry?
What are the key driving factors and challenges in the
North America HIV drugs industry?
What is the structure of the North America HIV drugs
industry and who are the key players?
Key
What is the degree of competition in the North America
Questions HIV drugs industry?
Answered in
What are the profit margins in the North America HIV
drugs industry?
the Report
1 P r e f a c e
2 S c o p e a n d M e t h o d o l o g y
2 . 1 O b j e c t i v e s o f t h e S t u d y
2 . 2 S t a k e h o l d e r s
2 . 3 D a t a S o u r c e s
2 . 3 . 1 P r i m a r y S o u r c e s
2 . 3 . 2 S e c o n d a r y S o u r c e s
2 . 4 M a r k e t E s t i m a t i o n
Table of 2 . 4 . 1 B o t t o m - U p A p p r o a c h 2 . 4 . 2 T o p - D o w n A p p r o a c h
2 . 5 F o r e c a s t i n g M e t h o d o l o g y
3 E x e c u t i v e S u m m a r y
4 I n t r o d u c t i o n
Contents 4 . 1 O v e r v i e w 4 . 2 K e y I n d u s t r y T r e n d s5 N o r t h A m e r i c a H I V D r u g s M a r k e t
5 . 1 M a r k e t O v e r v i e w
5 . 2 M a r k e t P e r f o r m a n c e
5 . 3 I m p a c t o f C O V I D - 1 9
5 . 4 M a r k e t F o r e c a s t
6 M a r k e t B r e a k u p b y D r u g s M a r k e t
6 . 1 M a r k e t P e r f o r m a n c e
6 . 2 I m p a c t o f C O V I D - 1 9
6 . 3 M a r k e t F o r e c a s t
7 N o r t h A m e r i c a H I V D r u g s M a r k e t : B r e a k u p b y D r u g C l a s s
7 . 1 N u c l e o s i d e R e v e r s e T r a n s c r i p t a s e I n h i b i t o r s
7 . 2 M u l t i - C l a s s C o m b i n a t i o n P r o d u c t s
7 . 3 P r o t e a s e I n h i b i t o r s
7 . 4 H I V I n t e g r a s e S t r a n d T r a n s f e r I n h i b i t o r s
7 . 5 N o n - N u c l e o s i d e R e v e r s e T r a n s c r i p t a s e I n h i b i t o r s
7 . 6 E n t r y I n h i b i t o r s — C C R 5 C o - R e c e p t o r A n t a g o n i s t
7 . 7 O t h e r s
8 N o r t h A m e r i c a H I V D r u g s M a r k e t : B r e a k u p b y D i s t r i b u t i o n
C h a n n e l
8 . 1 H o s p i t a l P h a r m a c i e s
8 . 2 R e t a i l P h a r m a c i e s
8 . 3 O n l i n e P h a r m a c i e s
8 . 4 O t h e r s
9 N o r t h A m e r i c a H I V D r u g s M a r k e t : B r e a k u p b y C o u n t r y
9 . 1 U n i t e d S t a t e s
9 . 1 . 1 H i s t o r i c a l M a r k e t T r e n d s
9 . 1 . 2 M a r k e t B r e a k u p b y D r u g C l a s s
Table of 9 . 1 . 3 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l
9 . 1 . 4 M a r k e t F o r e c a s t
9 . 2 C a n a d a
Contents 9 . 2 . 1 H i s t o r i c a l M a r k e t T r e n d s 9 . 2 . 2 M a r k e t B r e a k u p b y D r u g C l a s s
9 . 2 . 3 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l
9 . 2 . 4 M a r k e t F o r e c a s t
1 0 S W O T A n a l y s i s
1 0 . 1 O v e r v i e w
1 0 . 2 S t r e n g t h s
1 0 . 3 W e a k n e s s e s
1 0 . 4 O p p o r t u n i t i e s
1 0 . 5 T h r e a t s
1 1 V a l u e C h a i n A n a l y s i s
1 1 . 1 O v e r v i e w
1 1 . 2 R e s e a r c h a n d D e v e l o p m e n t
1 1 . 3 R a w M a t e r i a l P r o c u r e m e n t
1 1 . 4 M a n u f a c t u r i n g
F o r m o r e i n f o r m a t i o n , v i s i t :
h t t p s : / / w w w. im a rcg ro u p . co m / n o r t h - a m er i ca - h i v - d r u g s - m a r ke t / t o
c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024 IMARC Al l R ights Reserved
Th is Pub l i ca t ion and a l l i t ’ s con ten ts un less o therw ise men t i oned a re copy r i gh ted in the name o f
I n t e rna t i ona l Marke t Ana lys i s Research and Consu l t ing ( IMARC) . No pa r t o f t h i s pub l i ca t ion may be
rep roduced , repackaged , red i s t r i bu ted o r res o ld i n who le o r i n any pa r t . The pub l i ca t ion may a l so
no t be used i n any f o rm o r by and means g raph i c e lec t ron ic o r mechan ic a l , i nc lud ing pho tocopy ing ,
reco rd ing , t ap ing o r by i n fo rmat i on s to rage o r re t r ieva l , o r by any o the r f o rm, w i t hou t the exp ress
c ons en t o f I n t e rna t iona l Marke t Ana lys i s Research and Consu l t i ng ( IMARC) .
Disc la imer : Al l con ten ts and da ta o f t h i s pub l i c a t i on , i nc lud ing fo recas t s , da ta ana lys i s and op in ion
have been based on in f o rmat ion and sources be l ieved to be accu ra te and re l iab le a t t he t ime o f
pub l i sh ing . In t e rna t i ona l Ma rke t Ana l ys is Research and Consu l t ing makes no rep resen ta t ion o f
war ran t y o f any k ind as to t he acc u racy o r comp le teness o f any I n fo rmat i on p rov ided . IMARC
accep ts no l i ab i l i t y wha tsoever f o r any los s o r damage resu l t i ng f rom op in ion , e r ro rs o r
i naccu rac ies i f any f ound th is pub l i ca t ion .
IMARC, IMARC Group and G loba l Therapy I ns igh t Ser i es a re reg is t e red t rademarks o f I n te rna t iona l
Marke t Ana lys i s Research and Consu l t ing . A l l o the r t rademarks used i n th i s pub l i ca t i on a re
reg i s te red t rademarks o f t he i r r espec t i ve compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us:
Comments